MX2020011619A - Urolitina como mejorador inmunitario. - Google Patents

Urolitina como mejorador inmunitario.

Info

Publication number
MX2020011619A
MX2020011619A MX2020011619A MX2020011619A MX2020011619A MX 2020011619 A MX2020011619 A MX 2020011619A MX 2020011619 A MX2020011619 A MX 2020011619A MX 2020011619 A MX2020011619 A MX 2020011619A MX 2020011619 A MX2020011619 A MX 2020011619A
Authority
MX
Mexico
Prior art keywords
stem cell
urolithins
immune
relates
urolithin
Prior art date
Application number
MX2020011619A
Other languages
English (en)
Inventor
Christopher Rinsch
Anurag Singh
Davide D''amico
Pénélope Andreux
William Blanco-Bose
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807051.6A external-priority patent/GB201807051D0/en
Priority claimed from GBGB1807819.6A external-priority patent/GB201807819D0/en
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of MX2020011619A publication Critical patent/MX2020011619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a compuestos para usar a fin de generar una respuesta inmunitaria a un antígeno y/o mejorar, modular o aumentar una respuesta inmunitaria a un antígeno. Particularmente el uso de urolitinas. La invención también se refiere a mejoradores inmunitarios que comprenden urolitinas, métodos para usar tales mejoradores inmunitarios y procesos para la preparación de tales mejoradores inmunitarios. La invención también se refiere al uso de urolitinas en métodos para modular la función de las células madre, por ejemplo, mejorar la cantidad de células madre, promover la regeneración de las células madre y promover la diferenciación de las células madre.
MX2020011619A 2018-04-30 2019-04-30 Urolitina como mejorador inmunitario. MX2020011619A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1807051.6A GB201807051D0 (en) 2018-04-30 2018-04-30 Biological enhancer
GBGB1807819.6A GB201807819D0 (en) 2018-05-14 2018-05-14 Biological enhancer
PCT/EP2019/061093 WO2019211294A1 (en) 2018-04-30 2019-04-30 Urolithin a as immune enhancer

Publications (1)

Publication Number Publication Date
MX2020011619A true MX2020011619A (es) 2021-01-15

Family

ID=66379918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011619A MX2020011619A (es) 2018-04-30 2019-04-30 Urolitina como mejorador inmunitario.

Country Status (7)

Country Link
US (3) US10792276B2 (es)
EP (1) EP3787615A1 (es)
JP (1) JP2021522296A (es)
CN (1) CN112512517A (es)
BR (1) BR112020022159A2 (es)
MX (1) MX2020011619A (es)
WO (1) WO2019211294A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020011619A (es) 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.
US20240000747A1 (en) * 2020-11-26 2024-01-04 Daicel Corporation Sirtuin 6 activator
AU2022212883A1 (en) 2021-01-27 2023-08-17 Vandria Sa Urolithin derivatives and methods of use thereof
JP2024516187A (ja) * 2021-05-05 2024-04-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるためのウロリチン
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646177T3 (es) 2006-04-26 2017-12-12 The Regents Of The University Of California Usos terapéuticos de las urolitinas
PT2866804T (pt) 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
EP3087065B1 (en) 2013-12-23 2020-01-22 Amazentis SA Synthesis of urolithins
WO2016099947A1 (en) * 2014-12-19 2016-06-23 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
US20170304263A1 (en) * 2016-04-20 2017-10-26 John Michael Pezzuto Antioxidative stress compositions, methods of preparing and uses thereof
MX2020011619A (es) 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.

Also Published As

Publication number Publication date
US20230097072A1 (en) 2023-03-30
BR112020022159A2 (pt) 2021-01-26
WO2019211294A1 (en) 2019-11-07
US10792276B2 (en) 2020-10-06
US11426380B2 (en) 2022-08-30
US20190328703A1 (en) 2019-10-31
JP2021522296A (ja) 2021-08-30
CN112512517A (zh) 2021-03-16
EP3787615A1 (en) 2021-03-10
US20210085642A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MX2020011619A (es) Urolitina como mejorador inmunitario.
PH12018502348A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
GEP20227419B (en) Pd-1-binding molecules and methods of use thereof
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
JOP20180021A1 (ar) الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
NZ757915A (en) Anti-par2 antibodies and uses thereof
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
WO2015132675A3 (en) Methods and compositions for modifying the immune response
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
TN2018000341A1 (en) ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
SG10201801219VA (en) Anti-HER2 Antibodies
GB201206070D0 (en) Clostridium difficile antigens
WO2018236995A3 (en) METHODS FOR MODULATING REGULATORY T LYMPHOCYTES, REGULATORY B LYMPHOCYTES AND IMMUNE RESPONSES USING AVRIL-TACI INTERACTION MODULATORS
MX2022011973A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2021001129A (es) Metodo de purificacion de antigenos.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
AU2017261305A8 (en) DNA monoclonal antibodies targeting influenza virus
MY191596A (en) Igf-1r antibody and its use for the diagnosis of cancer
WO2015077434A3 (en) Pan pollen immunogens and methods and uses thereof for immune response modulation